Axsome Therapeutics, Inc.
AXSM
$148.98
$1.170.79%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 26.89% | 39.54% | 13.08% | 24.06% | -3.86% |
| Total Depreciation and Amortization | 16.98% | 12.69% | 16.49% | 19.14% | 18.24% |
| Total Amortization of Deferred Charges | -76.49% | -50.55% | 7.75% | 55.95% | 7.18% |
| Total Other Non-Cash Items | -3.37% | 15.17% | 21.51% | -47.14% | 150.68% |
| Change in Net Operating Assets | 74.72% | -162.63% | -49.10% | 273.69% | 156.09% |
| Cash from Operations | 105.61% | -7.68% | 18.88% | 13.70% | 65.21% |
| Capital Expenditure | 35.56% | 75.00% | -244.90% | -328.57% | 75.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 35.56% | 75.00% | -244.90% | -328.57% | 75.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -22,621.54% | -103,397.85% | -146.01% | -- | -- |
| Issuance of Common Stock | -23.72% | 146.01% | 1,366.81% | 1,434.24% | -12.28% |
| Repurchase of Common Stock | -78.01% | 33.13% | -167.99% | -90.36% | -33.24% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -22.43% | -200.90% | -40.43% | -183.74% | 49.29% |
| Cash from Financing | -30.05% | 140.24% | 2,565.88% | 712,300.00% | -8.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 90.48% | 113.34% | 73.62% | 60.53% | 156.86% |